Drug Development Pipeline for Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) and Facioscapulohumeral Muscular Dystrophy Type 2 (FSHD2)
The FSHD Society is now tracking the pipeline of potential therapies for FSHD being developed by pharmaceutical companies. The table includes therapies in early laboratory development all the way up to early and late clinical development.
View the FSHD Society Drug Development Pipeline here
If you have any questions do not hesitate to contact the registry curator at: firstname.lastname@example.org